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Freund’s Complete AdjuvantAbstract Aim: The present investigation was designed to evaluate anti-arthritic potential of ethyl
acetate fractions of chloroform extract from leaves of Barleria prionitis.
Materials and methods: Barleria prionitis L. leaves were defatted by petroleum ether and then succes-
sive extraction was done with chloroform and methanol by the hot Soxhlet extraction method. Chlo-
roform extract was further fractionated with solvent ethyl acetate to obtain EABP. This fraction was
evaluated at two doses 125 and 250 mg/kg, against formaldehyde-induced acute non immunological
and Freund’s Complete Adjuvant-induced chronic immunological arthritis in rats. Arthritis assess-
ment, paw volume, body weight, motor incoordination and nociceptive threshold were measured.
Haematological assessments of red and white blood cells, erythrocyte sedimentation rate, as well as
histopathological studies were also done on day 21, after animals were sacriﬁced.
Results: Dose dependent and signiﬁcant inhibition of oedema was observed in both acute as well as
chronic models. The extract at dose 250 mg/kg showed most potent and signiﬁcant (P 6 0.05–0.01)
paw oedema inhibition which is supported by the results of body weight, biochemical parameters,
motor incoordination and nociceptive threshold in Freund’s Complete Adjuvant-induced arthritis
model.
TreatmentwithEABPalso decreased the histopathological alterations induced byFreund’s Complete
Adjuvant.
Conclusion: In the present investigation, extract protects synovialmembrane by improving the health
status through haematinic parameters and exhibits promising anti-arthritic activity. This ﬁnding thus
supports the traditional use of Barleria prionitis for rheumatism. However, further studies are needed
to carry out the isolation of active constituents of the fraction responsible for the activity.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune multisys-
tem disease characterized by pain, synovial membrane inﬂam-
mation, peripheral joint inﬂammation, morning stiffness,
destruction of articular tissues and restricted joint move-
ment.1–3 The pathology of RA is complex and aetiology under-
200 M. Choudhary et al.lying RA remains unknown. It is clear that destructive changes
in the cartilage and bone, and bony outgrowths restricting
mobility of the joint occur in the patients.4 Arthritis can cause
severe disability and ultimately affects a person’s ability to
carry out everyday tasks, restricts the quality of life and causes
premature death.5 Any part of the body can become inﬂamed
or painful from arthritis. It is one of the most common inﬂam-
matory disorders affecting approximately 0.5–1.0% of global
adult population, with females being affected three times more
than males.6–8
Treatment of RA has moved from conventional strategies
such as non-steroidal anti-inﬂammatory drugs (NSAIDS),
corticosteroids, immunosuppressants, disease modifying
anti-rheumatic drugs (DMARDSs) to newer biological agents
such as TNF-a and monoclonal antibodies.9–11 Despite the
progress made in the treatment of disease, these treatments
fail to produce long term beneﬁts and produce serious
adverse effects such as gastrointestinal ulcer, renal morbidity,
cardiovascular complications, haematological toxicity and
nephrotoxicity, which limit their utility in the treatment of
the disease.12,13 Besides their side effects the current treat-
ment is also of high cost, so patients suffering from chronic
musculoskeletal disorders are likely to seek alternative meth-
ods for symptomatic relief. Thus complementary and alterna-
tive medicines may meet the requirement of large number of
patients suffering from this disease.14,15
Barleria prionitis L. (Family Acanthaceae) is a medicinal
plant found throughout South Africa, India, Sri-Lanka, and
tropical Asia. It is commonly known as Vajradanti.16,17 In tra-
ditional system of medicines, almost every part of the plant is
used for the treatment of various diseases like toothache, fever,
inﬂammation, gastrointestinal disorders, expectorant, boils,
glandular swellings, catarrhal affections, ulcers, tonic, diuretic,
itching of leprosy ulcers, lacerated soles of feet in rainy season
and the oil extract of plant is recommended to arrest the grey-
ing of hairs.18–21
Phytochemical studies of B. prionitis revealed the presence
of glycosides, steroids, tannins and ﬂavonoids.22 Iridoid glyco-
sides, shanzhiside methyl ester, 6-O-trans-p-coumaroyl-8-
O-acetylshanzhiside methyl ester, barlerin, acetyl barlerin,
7-methoxydiderroside and lupulinoside have been isolated
from aerial parts.23 Several reports including ours suggested
that plant is having antifungal,19,24 antiviral,25 anti-fertility,26
antioxidant,24,27,28 antidiabetic29 and gastroprotective30
activities.
Hence we attempted to investigate the anti-arthritic effect
of ethyl acetate fraction of chloroform extract of B. prionitis
in rodent formaldehyde and adjuvant induced arthritis models
to prove its importance in the treatment of rheumatism.2. Materials and methods
2.1. Plant collection
The leaves of B. prionitis were collected from Ashoka Nursery,
Gharunda, Karnal, Haryana, India in March, 2011. Authenti-
cation of leaves was carried out by Dr. H.B. Singh, Head, Raw
Materials Herbarium and Museum (RHMD), New Delhi. A
voucher specimen of the plant (Ref. No. NISCAIR/RHMD/
CONSULT/-2010-11/1497/95) has been preserved there for
future references.2.2. Preparation of extracts
The leaves were thoroughly washed under running tap water
so as to remove any type of contamination. Then washed
leaves were air dried in the shade, powdered in grinder and
passed through sieve of mesh size no-40. The dried powder
was ﬁrst defatted by petroleum ether and then successive
extraction was done with chloroform and methanol by the
hot Soxhlet extraction method. The chloroform extract was
concentrated in a rotary evaporator (Heidolph Instrument,
Laborota 4000, Germany) under reduced pressure. The dried
crude chloroform extract of B. prionitis (BPC) was collected
and preserved in an airtight glass container at 4 C–8 C.
2.3. Bioguided fractionation
Initially, 200 g of BPC was partition-fractionated with 1:1 (v/v,
volume ratio) of n-hexane and ethanol (50%), the mixture was
shaken vigorously and kept for about 30 min to make the two
layers separate. The upper layer consisting of n-hexane was
removed and concentrated in a rotary evaporator to obtain
hexane fraction (HBP). The same procedure was repeated with
the bottom layer by using equivalent volume of ethyl acetate to
get ethyl acetate fraction (EABP) and residual marc (RBP).
These were further used in the studies based on chemical
constituents.
2.4. Preliminary phytochemical screening
Phytochemical analysis was performed using standard proce-
dures to identify chemical constituents as described byKhandel-
wal.31 Precoated thin-layer chromatography plates of silica gel
60 F254+366 with support of aluminium sheets 0.1 mm thick
and 10 cm · 10 cm were used for the preliminary chromato-
graphic characterization of fraction. EABP fraction (10 mg)
was dissolved in methanol (mL). The mobile phase used was
chloroform:methanol = 7:3. The plates were sprayed with nat-
ural product reagent and polyethylene glycol (NP/PEG) for
detecting ﬂavonoids. Phenolic compounds are detected after
exposing the plates to ammonia vapours and immediate obser-
vation of ﬂuorescent spots under UV light. Anisaldehyde in sul-
phuric acid was used as detecting agent for steroids.
2.5. Analysis of extract
Stigmasterol and extract were accurately weighed, and dis-
solved in methanol to produce a solution containing
1.90 mg/25 ml. The sample was run for 20.00 min, and volume
of 5.00 ll was injected into the HPLC instrument. HPLC anal-
ysis was performed on an Hpersil C 18 150x 4.6 mm. (DRDC/
AD/36) column with a UV detector. The mobile phase con-
sisted of Methanol:Acetonitrile:Isopropyl alcohol: 40:20:20.
The ﬂow rate was 1.0 mL/min and the detection wavelength
of the UV detector was set at 228 nm. The column temperature
was set at 30 C.
2.6. Drugs and chemicals
Formaldehyde (S.d. Fine Chemicals Ltd., Mumbai, India),
FCA (Difco Laboratories, USA), Diclofenac (Symed Pharma-
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extraction and chemicals used for phytochemical analysis were
of analytical grade procured from approved organization.
2.7. Dose and route of administration
The dosages of EABP used in this study were 125 and 250 mg/
kg per day, which are based on our previous study.30 Fresh
drug solutions were prepared in Tween 80, (2% v/v) at the time
of administration and were administered Per Oral (p.o.) so as
to avoid any additional stress to the animals.
2.8. Preparation of reference drug
The reference anti-inﬂammatory drug diclofenac was dissolved
in normal saline for the study. The drug solution was freshly
prepared and administered orally at dose 4 mg/kg in volumes
not exceeding 10 mL/kg.
2.9. Animals
Healthy Sprague Dawley rats (200–300 g) of either sex pur-
chased from a disease free animal house of National Institute
of Pharmaceutical Sciences and Education Research, Mohali,
Punjab (India), were housed in the animal house, Institute of
Pharmaceutical Sciences, Kurukshetra University, Kurukshe-
tra, Haryana (India). The animals were fed with commercially
available feed and were maintained under standard conditions
of temperature (25 C± 5 C), relative humidity (55 ± 10%),
and 12/12 h light/dark cycle. They were transferred to the lab-
oratory twelve hours prior to the experiments and given only
water ad libitum. In all the experiments, the animals were kept
in cages with raised ﬂoors of wide mesh, to prevent coproph-
agy. The animals were housed and cared for in accordance
with the Federal Government Legislation on animal care. Pro-
tocols for the study were approved by the Institutional Ani-
mals Ethical Committee (IAEC) for Animal Care (Register
Number: 562/GO/02/a/CPCSEA) and were in accordance with
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA) guidelines, Government
of India.
2.10. Experimental procedure
2.10.1. Acute non-immunological formaldehyde-induced arthritis
in rats
Sprague-Dawley rats were divided into ﬁve groups of six ani-
mals each. Baseline recording of the paw volume was made
by using plethysmometer (Ugo Basile 7140, Italy).32 Group I
(vehicle control) received Tween 80, (2% v/v, orally), group
II (negative control) received formaldehyde, group III and
IV received EABP (125 and 250 mg kg1 body weight/rat/
day, orally), respectively and animals of group V received dic-
lofenac sodium (4 mg kg1 body weight/rat/day, orally) for
10 days. On day 1, 30 min after the drug administration, acute
non-immunological arthritis was induced by sub plantar injec-
tion of 0.1 ml formaldehyde (2% v/v) into the right hind paw
of all the animals except group I animals and repeated on day
3. Arthritis was assessed by measuring the mean increase in
paw volume over a period of 10 days.2.10.2. Chronic immunological FCA-induced arthritis in rats
2.10.2.1. Induction of arthritis. Adjuvant arthritis was induced
in rats according to the method described by Newbould, (1963)
with slight modiﬁcation.33 In this process, the initial hind paw
volumes (both left and right) of the experimental animals were
measured by water displacement plethysmography. Following
anaesthesia with ketamine (120 mg/kg), 0.1 ml of FCA (a sus-
pension of heat killed Mycobacterium tuberculosis in mineral
oil) was then injected into the subplantar tissue of the right
posterior paw. The volumes of the injected (ipsilateral), pri-
mary response; and un-injected (contralateral), secondary
response; were measured on alternate days from 2 to 21 days
after the adjuvant injection. Unilateral inﬂammatory oedema
of the ipsilateral paw peaking at around days 6–8 was indica-
tive of successful induction of adjuvant arthritis.
2.10.2.2. Experimental procedure. Grouping of animals is same
as described in formaldehyde induced non-immunological
arthritic model.
Group I: vehicle control (Tween-80 (2% v/v, orally).
Group II: FCA control (Tween 80 (2% v/v, orally).
Group III: EABP (125 mg kg1 body weight/rat/day, orally).
Group IV: EABP (250 mg kg1 body weight/rat/day, orally).
Group V: diclofenac sodium (4 mg kg1 body weight/rat/
day, orally)
Thirty minutes after administration of vehicle/drug, arthritis
was induced by sub plantar injection of FCA. This was desig-
nated as day 0. After immunization with FCA, all groups were
maintained on vehicle/drug treatment for 20 more days.34
Anti-arthritic activity of active fraction was evaluated on paw
volume, arthritic score, painwithdrawal latency and fall off time
on days 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 and day 21.Moreover body
weights of animals were monitored regularly during the course
of the experiment. On day 21, blood was withdrawn by retro-
orbital puncture for assessment of haematological parameters
and animals were sacriﬁced under light ether anaesthesia to
study histopathology of joints.
2.11. Parameter assessment
2.11.1. Arthritic score
Photographs of the arthritic rats were taken on the 21st daywith
a digital 10-megapixel (Panasonic DMC-FS42) camera. Mor-
phological feature of arthritis wasmonitored by the same person
for all rats on the 21st day according to the extent of erythema
and oedema of the joints, using the criteria as follows: normal
paw = 0, mild swelling and erythema of digits = 1, moderate
swelling and erythema of digits = 2, severe swelling and ery-
thema of digits = 3, gross deformity and inability to use
limbs = 4.35 The arthritic score for each rat on day 0 was deter-
mined to be 0. The scores for each pawwere then added to get the
total arthritic score. Thus, the maximum possible score for each
animal was 16.
2.11.2. Paw volume
The paw volume of both hind paws was measured just before
FCA injection on day 0 and on alternate days after 2–21 days
using a plethysmometer.
2.11.3. Anti-nociceptive activity
The apparatus consists of a hot plate on which the rats were
placed for testing (Eddy’s Hot Plate Method).36 Pain threshold
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drawal of any paw) with a maximum cut-off time 15 sec for all
groups.
2.11.4. Motor incoordination test
Motor incoordination was evaluated by Rota-rod apparatus as
described earlier.37 Rats were placed on the rotating rod of
device for 1 min. The time taken for the falling of rats from
the roller, during the period of 1 min was recorded.
2.11.5. Measurement of organ weight
Rats were sacriﬁced with ether on the 21st day, the spleen and
thymus were removed, and weight of the organs was recorded
and corrected for 100 g body weight.
2.11.6. Haematological assessment
On the 21st day, blood was withdrawn from each animal
through the retro orbital plexus into a test tube containing
anticoagulant (5% EDTA) and haematological parameters
were determined. The red blood cells (RBC) were determined
by the method of Huxtable,38 white blood cell count (WBC)
was determined using Raghuramulu.39 Haemoglobin concen-
tration was estimated by the cyan-methemoglobin method of
Drabkin and Austin.40 Erythrocyte sedimentation rate (ESR)
was determined using the Wintrobe method.41
2.12. Histological analysis
After sacriﬁce on the 21st day, ankle joints were removed from
the hind paw, weighed and ﬁxed for 24 h in 10% formalin. After
decalciﬁcation in 5% formic acid, processed for parafﬁn embed-
ding, tissue sections (5 lm thick) were stained with haematoxy-
lin and eosin. An experienced pathologist (Dr. Neeraj Mittal),
unaware of the different drug treatment evaluated the slides
under light microscope for the presence of hyperplasia of syno-
vium, inﬂammatory cells, ﬁbrosis and destruction of joint space.
2.13. Statistical analysis
The results were expressed as mean ± SEM. Statistical com-
parison was made between the drug-treated group and
arthritic-control group. Statistical difference between two
means was determined by one-way ANOVA followed by Dun-
nett’s multiple comparison test using In-Stat 3 statistical com-
puter software. Only those mean values showing statistical
difference P< 0.01 or P< 0.05 were considered as statisti-
cally signiﬁcant.
3. Results
3.1. Preliminary phytochemical screening
Chromatographic study of ethyl acetate fraction of chloroform
extract of leaves showed the presence of terpenoids, alkaloids,
ﬂavonoids, saponins and phenols. Further, HPTLC and
HPLC studies conﬁrmed the presence of stigmasterol
(0.0465% w/w) in the EABP (Fig. 1).3.2. Formaldehyde induced paw oedema
Fig. 2 summarizes the effect of EABP (125 and 250 mg/kg) and
diclofenac on 2% formaldehyde induced arthritis. EABP
signiﬁcantly suppressed the joint swelling when compared with
arthritic control between day 4 and day 10 post formaldehyde
treatments. Even though both the doses of extract exhibited
signiﬁcant inhibition, dose 250 mg/kg of extract showed activ-
ity comparable with standard from day 8 to day 10.
3.3. FCA induced arthritis
Subplantar administration of FCA in the rat paw resulted in
the progressive increase in the volume of the ipsilateral
(injected) paw as well as contralateral (non-injected) paw.
The difference in the volume of ipsilateral and contralateral
paw between FCA and drug treated rats was statistically sig-
niﬁcant in a dose dependent manner. Biphasic response was
observed, consisting of acute and polyarthritis phases. In the
acute phase of disease erythema of one or more ankle joints
was seen followed by involvement of the metatarsal and
inter-phalangeal joint (Fig. 3).
3.3.1. Effect of EABP on arthritic index
All the animals administered with FCA results in increased
arthritic score in one or more hind paws, which was a biphasic
response. The adjuvant ipsilateral paw joints started to show
swelling and rigidity around 8–10 days in the arthritis control
group, and maximum level of arthritic score was observed on
day 18. As shown in Fig. 4 rats treated with 125 and 250 mg/kg
of extract showed a signiﬁcant (P< 0.01) and dose dependent
decrease in arthritic score from day 10 onward till the end of
the study, i.e. day 21 as compared to FCA control animals.
Although both the doses showed a signiﬁcant decrease in the
arthritic score, at 250 mg/kg, EABP showed suppressive effect
comparable to standard drug.
3.3.2. Effect of EABP on body weight
There was less body weight gain of FCA control rats as com-
pared to vehicle control rats, due to generation of immune
response (Fig. 5). In EABP (125 and 250 mg/kg) and diclofe-
nac treated arthritic rats, signiﬁcant weight gain was observed
as compared to disease control animals.
3.3.3. Effect of EABP on paw volume
Immunization with subplantar administration of FCA pro-
duced an increase in volume of both the injected as well as
non-injected paws in all the FCA treated rats compared to
vehicle control. There was maximum paw volume on day 8,
after that a slight decrease in paw volume was observed from
day 8 to day 12 in FCA treated rats. After 12th day a progres-
sive increase in paw volume was seen till the end of study. On
treatment with EABP (125 and 250 mg/kg) a signiﬁcant
(P< 0.01) and dose dependent decrease in the primary as well
as secondary lesions was seen after 10 days of study. Effect
observed with 250 mg/kg was comparable with standard drug
diclofenac (Fig. 6).
Figure 1 HPTLC (A) and HPLC ﬁngerprinting of Stigmasterol (B) and EABP (C) showing the presence of stigmasterol (0.0465% w/w)
in the extract.
Figure 2 Effect of EABP (125 and 250 mg/kg) on formaldehyde-
induced paw oedema. Values are plotted as the mean ± SEM,
n= 6 in each group; signiﬁcant reduction in paw volume was
analysed by one-way analysis of variance followed by Dunnett’s
multiple comparison test using Graph pad Instat Software;
*P< 0.05, **P< 0.01 compared to the formaldehyde control
group.
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There was consistent decrease in paw withdrawal threshold
observed in FCA treated rats compared to vehicle control ani-
mals and pain threshold was observed to be lowest on day 8.
Administration of 250 mg/kg dose of EABP and diclofenac
showed the decreased withdrawal latency from day 2 to day
8, after that there was signiﬁcant improvement in the paw
withdrawal threshold from day 10 as compared to the FCA
treated control group. Little improvement was observed in
EABP (125 mg/kg) but that was not signiﬁcant compared to
FCA control (Fig. 7A).
3.3.5. Effect of EABP on fall off time
Mean fall off time in rota rod test was determined for the
assessment of motor in-coordination. Sub plantar administra-
tion of FCA results in the decrease in fall off time in the FCA
treated group as compared to the vehicle control group. Rats
treated with EABP (125 and 250 mg/kg) and diclofenac
(4 mg/kg) signiﬁcantly increased (P< 0.05) fall off time from
day 2 till day 21 as compared to the FCA control group
(Fig. 7B).
Figure 3 Morphological representations of the rat paw after subplantar administration of FCA. (A) vehicle control (B) FCA treated rats
(C) EABP (125 mg/kg) (D) EABP (250 mg/kg) (E) diclofenac (4 mg/kg) treated rats.
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There was a decrease in thymus weight whereas the mean
spleen weight was increased in the FCA treated rats as com-
pared to the vehicle control group (Table 1). Rise in spleen
weight was signiﬁcantly (P< 0.01) inhibited in rats treated
with EABP (125 and 250 mg/kg) and diclofenac (4 mg/kg) as
compared to FCA treated rats. Only treatment with dose
250 mg/kg of EABP and diclofenac attenuated the decreased
weight of the thymus, signiﬁcantly (P< 0.01).
3.3.7. Effect of EABP on haematological parameters
There was a non-signiﬁcant difference (P > 0.05) in W.B.C
and R.B.C levels in EABP (125 and 250 mg/kg) and diclofenac
(4 mg/kg) treated rats when compared to FCA arthritic ani-
mals (Table 2). Increased ESR level in FCA treated rats was
observed as compared to vehicle treated rats. Treatment with
EABP (125 and 250 mg/kg) as well as diclofenac (4 mg/kg) sig-niﬁcantly (P< 0.01) attenuated this increased level of ESR as
compared to FCA control rats. Furthermore in the diclofenac
treated group only, signiﬁcant (P< 0.01) improvement in hae-
moglobin level was observed.
3.3.8. Effect of EABP on histology of joints
Histopathological studies of the tibiotarsal joints show
destructive lesions in connective tissue, vascularity into joint
space, and granuloma formation in the FCA treated animals
(Fig. 8). There was present normal connective tissue structure
with the absence of necrosis in the tibiotarsal joint of the vehi-
cle control group. Diclofenac treatment showed normal con-
nective tissue of tibiotarsal joint with the presence of lesser
oedema and absence of necrosis. EABP treated rats produced
knee joint protection compared to arthritic rats by reducing
the inﬂammation and necrosis. Rats treated with EABP
(250 mg/kg) showed mild necrosis with oedema but granuloma
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Figure 4 Effects of EABP (125 and 250 mg/kg) on arthritic score
in FCA model. Values are plotted as the mean ± SEM, n= 6 in
each group; Decreased arthritis score was analysed by one-way
analysis of variance followed by Dunnett’s multiple comparison
test using Graph pad Instat Software; *P< 0.05, **P< 0.01
compared to FCA control.
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Figure 5 Effects of EABP (125 and 250 mg/kg) on body weight
in FCA model. Values are plotted as the mean ± SEM, n= 6 in
each group; signiﬁcant reduction in body weight was analysed by
one-way analysis of variance followed by Dunnett’s multiple
comparison test using Graph pad Instat Software; *P< 0.05,
**P< 0.01 compared to FCA control.
Figure 6 Effects of EABP (125 and 250 mg/kg) on (A) ipsilateral
paw and (B) contralateral paw. Values are plotted as the
mean ± SEM, n= 6 in each group; signiﬁcant reduction in paw
volume was analysed by one-way analysis of variance followed by
Dunnett’s multiple comparison test using Graph pad Instat
Software; *P< 0.05, **P< 0.01 compared to FCA control.
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showed granuloma formation along with oedema and necrosis
with few inﬂammatory cells.
4. Discussion
Rheumatoid arthritis is a chronic, inﬂammatory, autoimmune
disorder affecting about 1% of adults worldwide.6,42 In recent
years, natural products are becoming an important area of
interest for the development of new therapeutic entities due
to their higher safety and lower cost. The present investigation
examined the anti-arthritic activity of ethyl acetate fraction of
chloroform extract of B. prionitis. Dosage selection was based
on the previous research conducted by our research group.30
We investigated the activity of fraction on rheumatoid arthritis
by ﬁrstly evaluating against formaldehyde induced paw
oedema, which is a very common and simple method for
screening of anti-arthritic potential. Formaldehyde inducedjoint oedema inhibition has been commonly used as an exper-
imental animal model for evaluation of anti-arthritic activity.43
Biphasic pain, i.e. early neurogenic followed by tissue medi-
ated response and localized inﬂammation is produced by
formaldehyde injection into the rat paw.44 In the present inves-
tigation, EABP inhibited the paw oedema, induced by formal-
dehyde injection. The effect may be due to certain changes in
the inﬂammatory response which are comparable with
diclofenac.
The anti-arthritic effect of EABP was further conﬁrmed by
Freund’s Complete Adjuvant arthritis in rats. The FCA model
is a well-established rat model to study the inﬂammation.45
FCA consists of inactivated and dried mycobacterium, which
effectively stimulates cell mediated immunity and ultimately
leads the immunoglobulin production. The FCA induced
arthritis shows pronounced swelling in the hind paw (Primary
arthritis) which persists for a week and where generation of
prostaglandin occurs. After few days, swelling in the contralat-
eral as well as in front paw was seen (Secondary chronic arthri-
tis) along with appearance of arthritic nodules in the ear and
tail.46,47 RA is an autoimmune disorder of unknown aetiology
that is characterized by release of various inﬂammatory medi-
ators. In recent investigations role of pro-inﬂammatory cyto-
kines such as tumour necrosis factor-a (TNF-a), interlukin-
1b (1L-1b), 1L-6, 1L-8, MCSF, interferons and platelet derived
growth factor (PDGF) has been revealed for the limb and joint
swelling along with pain, joint destruction, deformity and
Figure 7 Effects of EABP (125 and 250 mg/kg) on (A) Pain
threshold (s) and (B) Fall off time (s). Values are plotted as the
mean ± SEM, n= 6 in each group; signiﬁcant reduction in fall
off time and pain threshold were analysed by one-way analysis of
variance followed by Dunnett’s multiple comparison test using
Graph pad Instat Software; *P< 0.05, **P< 0.01 compared to
FCA control.
Table 1 Effect of EABP (125 and 250 mg/kg) treatments on thymu
Groups Dose (mg/kg) Spl
Vehicle control – 18
FCA control – 249
EABP 125 231
EABP 250 212
Diclofenac 4 209
Values are plotted as the mean ± SEM, n= 6 in each group; signiﬁcan
Dunnett’s multiple comparison test using Graph pad Instat Software; *P
Table 2 Effect of EABP (125 and 250 mg/kg) on haematological p
Treatment Dose (mg/kg) RBC (·106/lL)
Vehicle control – 8.05 ± 0.12
FCA control – 7.58 ± 0.11
EABP 125 mg/kg 8.00 ± 0.07
EABP 250 mg/kg 7.96 ± 0.08
Diclofenac 4 mg/kg 8.00 ± 0.12
Values are plotted as the mean ± SEM, n= 6 in each group; signiﬁcant
Dunnett’s multiple comparisons test using Graph pad Instat Software; **
206 M. Choudhary et al.disability.48,49 The present study revealed that, paw volume
was increased in adjuvant treated rats. EABP administration
delayed the onset and attenuated the severity of disease as
revealed by a decrease in volume of both paws via inhibition
of release of inﬂammatory mediators, thus indicating its anti-
inﬂammatory potential. The effects shown by extract at dose
250 mg/kg were comparable to standard drug.
The diclofenac, a non-steroidal anti-inﬂammatory drug was
used for comparison because it is commonly prescribed for the
treatment of arthritis and its action is mainly through the inhi-
bition of cyclooxygenase and prostaglandin production.50,51 In
the present study diclofenac sodium prevented the spread of
adjuvant induced arthritis which is consistent with previous
reports of various researchers.52,53
The severity of arthritis was expressed as arthritic score is
the index of joint inﬂammation, being the sum of measures
of four paws subtracted by measures before immunization.54
Arthritic score of EABP treated groups was signiﬁcantly lower
than FCA induced rats, thus distinguish the immunosuppres-
sive effects of fraction from its anti-inﬂammatory effect. Pro-
gression of disease status and response to anti-inﬂammatory
therapy are indirectly linked with change in body weight.55
RA is associated with weight loss and loss of lean body mass,
known as rheumatoid cachexia which leads to the decreased
physical activity, muscle strength and decreased daily perfor-
mance.56–58 Some researchers have reported the altered meta-
bolic activities in the arthritic rats.59 Due to inﬂammatory
condition, intestinal absorption of 14C-glucose and 14C-leucine
was reduced and treatment with anti-inﬂammatory drugs has
improved the decreased absorption capacity.60,61 In the present
investigation, the FCA treated rats showed less body weight
gain as compared with diclofenac and extract treated arthritic
rats. Thus, body weight gain may be due to the restoration of
the absorption capacity of the intestine that shows effective
management of rheumatoid cachexia.s and spleen weight.
een weight (mg/100 g b.wt.) Thymus weight (mg)
5.5 ± 4.09 103.5 ± 2.01
.16 ± 2.71 81.00 ± 0.81
.50 ± 1.56** 84.50 ± 0.76
.00 ± 1.06** 89.50 ± 1.33**
.83 ± 4.20** 91.00 ± 0.96**
t change was analysed by one-way analysis of variance followed by
< 0.05, **P< 0.01 compared to FCA control.
roﬁle.
WBC (·103/lL) Hb (g/dL) ESR (mm)
11.48 ± 0.16 13.21 ± 0.10 3.05 ± 0.07
14.15 ± 0.18 11.56 ± 0.18 9.43 ± 0.12
12.88 ± 0.61 12.40 ± 0.37 6.31 ± 0.19**
12.85 ± 0.72 12.43 ± 0.33 4.08 ± 0.12**
12.21 ± 0.43 13.08 ± 0.09** 3.53 ± 0.10**
reduction was analysed by one -way analysis of variance followed by
P< 0.01 compared to FCA control.
Figure 8 Histology of the arthritis developing 21 days after immunization with FCA compared with unimmunized Sprague Dawley rats.
(A) Vehicle control; (B) FCA control; (C) EABP (125 mg/kg); (D) EABP (250 mg/kg); (E) Diclofenac (4 mg/kg). Magniﬁcation · 100;
thickness: 5 lm.
Anti-arthritic activity of Barleria prionitis Linn 207It has been evidenced by previous studies that Eddy’s hot
plate is a quantitative method for determination of hyperalge-
sia related to behaviours.36,62 Inhibiting controls caused by
long standing nociceptive input from the contra lateral
arthritic limb is probably involved in the alterations occurred
after an acute pain stimulus in the non-affected limb. Study
of an earlier researcher shows that increased pain sensitivity
is linked with decreased hyperalgesia latency .36 In the present
investigation we observed that EABP showed signiﬁcant
improvement in nociceptive threshold.
The spleen is a vital organ which serves as the available
source of cells and antibody formation, known to be involved
in immunological response in adjuvant arthritis.63 In the spleen
of arthritic rats, increased cellularity is observed. Due to
splenomegaly, increase in the weight of spleen occurs.64 EABP
attenuated the increased weight of spleen and decreased weight
of thymus may be due to the immune-stimulant effect.The erythrocyte sedimentation rate is elevated in various
stress conditions, cell necrosis and inﬂammation.65 The ESR
is an indirect method for the measurement of inﬂammation
in the body. Due to protein production in inﬂammation,
erythrocytes move closer, stack up in a group, become denser
and settle faster. With the increase in erythrocyte settling rate,
erythrocyte sedimentation rate also increases.66 The signiﬁcant
low level of ESR in the EABP and diclofenac treated arthritis
rats indicates their anti-inﬂammatory potential.
Histopathological studies of the paws contribute towards
the treatment of arthritis with EABP despite evidence of
pathology in the arthritic animals treated with the reference
drug.
The anti-arthritic effect of fraction (EABP) of chloroform
extract of B. prionitis, established in this study could be attrib-
uted to the presence of ﬂavonoids, triterpenoid, saponins, tan-
nins and steroids detected after phytochemical screening of the
208 M. Choudhary et al.fractions. Triterpenoids are known to inhibit histamine release
from mast cells and exert anti-inﬂammatory effects. Non-spe-
ciﬁc anti-arthritic activity may be due to the combined effect of
the different phytoconstituents present.
5. Conclusions
On the basis of the results obtained in the present study we
suggest that possibly, the anti-arthritic potential of EABP
may be through protection of synovial membrane, vascular
permeability, prevention of cartilage destruction, thereby
improving the health status through haematinic properties.
The effect may be due to the inhibition of phospholipase A2
and prostaglandins due to similar effect of diclofenac. The
results obtained in the present study demonstrate beneﬁcial
effects of plant during recovery from arthritis by including
Hb, ESR and body weight along with clinical signs including
paw oedema, thermal hyperalgesia and histopathological
examination. The study established that the ethyl acetate frac-
tion of B. prionitis possesses anti-arthritic activity in Sprague
Dawley rats.
However, further studies are needed to identify and isolate
the possible phytoconstituent(s) involved in the anti-arthritic
activity, which would facilitate the use of B. prionitis in inﬂam-
matory disease.
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